Shailender Bhatia, MD, on Merkel Cell Carcinoma: Study Results on Retifanlimab

Posted: Thursday, January 6, 2022

Shailender Bhatia, MD, of the University of Washington, discusses phase II findings from the POD1UM-201 trial, which suggest that retifanlimab, an anti–PD-1 monoclonal antibody, may be a potential new treatment option for patients with advanced or metastatic Merkel cell carcinoma. Its treatment schedule of once every 4 weeks without the need for premedications would be less burdensome for patients, Dr. Bhatia noted.